NCT00966251View on ClinicalTrials.gov

Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Primary Hepatocellular Carcinoma
Interventions
DRUG

CT-011

CT-011

Trial Locations (1)

Unknown

Hadassah Medical Center, Jerusalem

Sponsors

Lead Sponsor

CureTech Ltd
All Listed Sponsors
collaborator

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

lead

CureTech Ltd

INDUSTRY